News

The trial is designed to assess the role of edoxaban in VTE patients associated with cancer (other than basal-cell or squamous-cell carcinoma of the skin) for whom long-term

In the clinical program, statistically significant differences in muscle strength as compared to a matched external control cohort and a favorable safety profile were observed. "We are excited

The Vectibix treatment arm further showed statistical significance for all key secondary endpoints including OS in patients with wild-type RAS (absence of mutations in exons 2, 3 and

With this patent, CellResearch’s stance as a global leader of stem cell technology expertise is further solidified, and allows the company’s continued efforts in making Cord Lining Stem

The collaboration, which was facilitated by the Johnson & Johnson Innovation Center in Boston, utilizes Emulate’s Organs-on-Chips to advance the clinical goals for three Janssen R&D programs at

Topline results from this study are now expected in Q1 2016. GPR84 was identified as a target for these diseases through Galapagos’ target discovery platform and GLPG1205 is

These funds will be used to initiate a proof-of-concept study of the CRTH2 antagonist OC459 in severe eosinophilic asthma, and to accelerate the development of both OC459 and

CAT-1004 is an oral small-molecule that the Company believes has the potential to be a disease-modifying therapy for DMD patients, regardless of the underlying dystrophin mutation, by inhibiting

Altius (higher in Latin) will be pioneering new technologies and approaches for decoding how genes are controlled and how a cell’s "operating system" functions in health and disease.